Norris Medicines Limited is an India-based company, which is focused on the health care industry. The Company is engaged in the manufacturing and exporting medicines and injections. The Company’s product categories include antibiotic, anti-inflammatory and analgesic range, G. I. range, dermatological range, nutrition range, anti-malaria, anti-emetic, cough/cold range, dental range, diabetics and cardiac, and miscellaneous range. Its antibiotic products include Arizon-100, Arizon-250, Arizon-500, Cefan-dry syurp, and Cefan DT-50. Its G.I. products include Denzym Syrup, Denzym Oral Drop, Ezynor-20, Regus-DSR, Sucrinor and Rinotac. Its dermatological products include Clobec-G, Gabax, Morfit Plus, Novadin-M, Silwon-C and Tioderm. Its nutrition products include Cand XP, Cand Fort, Can D suspension and Hemfit Plus Syrup. It has two plants situated at GIDC, Ankleshwar, Gujarat. Both the plants of the Company are World Health Organization Good Manufacturing Practices (WHO GMP) approved.As of 25 May 2026, NORRIS MEDICINES LTD. share price is ₹13.00. The stock opened at ₹13.99, compared to its previous close of ₹13.00. During today's trading session, NORRIS MEDICINES LTD. share price moved in the range of ₹13.00 to ₹13.99, with an average price of ₹13.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹13.00 and a high of ₹13.99.
The market capitalization of NORRIS MEDICINES LTD. is ₹13 Crs, with a P/E ratio of -23.2 and a dividend yield of 0.00%.